The EMA and FDA have recently approved lebrikizumab for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. Previously, the safety and efficacy of lebrikizumab were reported up to 52 weeks. Now, Prof. Diamant Thaçi (University of Lübeck, Germany) presented the 3 years results of continuous treatment of lebrikizumab in responders from the phase 3 studies ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) [1].
Patients who completed week 52 of the parent trials were able to enrol in the long-term extension study ADjoin (NCT04392154) and received the same dose as in the maintenance phase of ADvocate 1 and 2. Maintenance of response was evaluated for the Investigator Global Assessment (IGA), EASI75, and EASI90 response.
“Roughly all patients can maintain the treatment response they achieved at 16 weeks,” said Prof. Thaçi. This was noted in the as-observed analysis but also in the stricter non-responder imputation. By week 152, over 80% of participants who had initially achieved clear or almost clear skin (IGA 0/1) maintained this outcome. EASI75 response showed a similar response. Interestingly, only a minor difference was seen between a treatment interval of every 2 or every 4 weeks (EASI75 response of 90.5% and 94.1%, respectively).
EASI90 treatment responses were not only maintained but slowly increased up to 3 years: 79.4% of participants treated every 4 weeks and 86.8% of those treated every 2 weeks reached an EASI90 response at 152 weeks.
Throughout the study, intermittent use of topical corticosteroids was allowed. However, roughly 90% of participants did not need any rescue medication. “This is remarkable and shows the power of this treatment to control the disease in a long-time manner,” Prof. Thaçi concluded.
The biologic was overall well tolerated and showed no new long-term safety signals.
- Thaçi D. Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial. D1T01.2E, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support provided by Dr Susanne Kammerer
Posted on
Previous Article
« Anti-KIT antibody: the next frontier in CSU treatment? Next Article
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib »
« Anti-KIT antibody: the next frontier in CSU treatment? Next Article
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
November 18, 2021
Ruxolitinib cream: a safe treatment for elderly AD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com